NPC Archive Item: DURATION-3; when added to metformin or metformin plus a sulphonylurea, weekly exenatide improves disease-orientated outcomes compared with insulin glargine

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 Long-acting exenatide 2mg once weekly was more effective at reducing HbA1c than insulin glargine (titrated to glucose targets), when added to metformin or metformin plus sulphonylurea, […]

NPC Archive Item: DURATION-2; weekly exenatide in type 2 diabetes has disease-orientated outcome benefits when compared with metformin plus either sitagliptin▼ or pioglitazone▼

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 Exenatide 2mg once weekly injection was more effective at reducing HbA1c than maximum oral doses of either sitagliptin▼ or pioglitazone▼, when added to metformin, in the […]

NPC Archive Item: Extended DURATION-1 trial of exenatide weekly in type 2 diabetes demonstrates sustained reduction in HbA1c; no patient-orientated outcomes reported

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 November 2010 We have previously discussed the 30-week DURATION-1 trial of long-acting exenatide 2mg once weekly versus 10micrograms exenatide▼ twice daily in adults with type 2 diabetes (T2DM). In […]

NPC Archive Item: Key licensing studies for indacaterol in COPD published

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 31 August 2010 Indacaterol▼ inhaled once daily improved trough FEV1 at 12 weeks compared to placebo in patients with moderate to severe COPD. Results from the 52-week INVOLVE study […]

NPC Archive Item: Pre-planned analysis of PLATO study of aspirin plus ticagrelor or clopidogrel in patients undergoing early invasive intervention for ACS

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 August 2010 Early invasive intervention for acute coronary syndrome was planned for 13,408 patients in this pre-specified analysis of the PLATO study (total n=18,624). After 12 months, ticagrelor plus […]

NPC Archive Item: Lasofoxifene for postmenopausal osteoporosis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15 April 2010 In the PEARL study of 8,556 women with postmenopausal osteoporosis, lasofoxifene 0.5mg daily reduced the risk of radiographic vertebral fractures after three years. At the end of […]

NPC Archive Item: Disappointing results for cangrelor in patients undergoing PCI

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 29 March 2010 Intravenous cangrelor has failed to show a benefit on the primary end point of a composite of death, myocardial infarction (MI) or ischaemia-driven revascularisation 48 hours […]

NPC Archive Item: Cladribine – another potential new oral treatment for MS?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 March 2010 Oral cladribine, given as one of two cumulative doses (either 3.5mg or 5.25mg/kg) in short courses, was more effective at preventing relapse than placebo in the […]